Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies

Journal of Urology

Volumn 181, Issue 6, 2009, Pages 2634-2640

  Marks, Leonard S ^a   Gittelman, Marc C ^b   Hill, Lawrence A ^c   Volinn, Weining ^c   Hoel, Gary ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b South Florida Medical Research   (United States)

^c Watson Laboratories   (United States)

Author keywords

KMD 3213; prostatic hyperplasia; signs and symptoms

Indexed keywords

PLACEBO; SILODOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; TIME FACTORS;

EID: 67349102059     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.034     Document Type: Article

References (21)

1. Wei J.T., Calhoun E.A., and Jacobsen S.J. Benign prostatic hyperplasia. In: Litwin M.S., and Saigal C.S. (Eds). Urologic Diseases in America (2007), National Kidney and Urologic Diseases Information Clearinghouse, Bethesda, MD. http://kidney.niddk.nih.gov/statistics/uda/ NIH publication 07-5512: 43-67. Available at: http://kidney.niddk.nih.gov/statistics/uda/ (updated February 2007). Accessed August 28, 2008
2. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 7 (2005) S3
3. 1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4 (2007) 368
4. 1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15 (2008) 193
5. 1c-)adrenoceptor subtype. Br J Pharmacol 115 (1995) 781
6. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113 (1994) 723
7. 1-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 164 (2000) 578
8. Chapple C., and Andersson K.E. Tamsulosin: an overview. World J Urol 19 (2002) 397
9. de Mey C., Michel M.C., McEwen J., and Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 33 (1998) 481
10. 1-adrenoceptors and native tissues. Mol Pharmacol 48 (1995) 250
11. 1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 296 (2001) 160
12. 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 315 (1996) 73
13. 1a-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291 (1999) 81
14. Minipress (prazocin hydrochloride) prescribing information. MedWatch Web site. http://www.fda.gov/medwatch/safety/2001/jun01.htm (updated June 2001). Accessed August 28, 2008
15. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 (2006) 1019
16. Höfner K., Claes H., De Reijke T.M., Folkestad B., and Speakman M.J. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36 (1999) 335
17. 1-adrenoceptor antagonists on male sexual function. Drugs 66 (2006) 287
18. Roehrborn C.G., Van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92 (2003) 257
19. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51 (1998) 892
20. Madersbacher S., Marszalek M., Lackner J., Berger P., and Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 51 (2007) 1522
21. American Urological Association. Clinical Guidelines: Management of BPH ('03/Updated '06). Chapter 3 with Appendix: results of the treatment outcomes analyses. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph Accessed December 3, 2008